Sanctuary Advisors LLC Takes $1.78 Million Position in Zimmer Biomet Holdings, Inc. $ZBH

Sanctuary Advisors LLC acquired a new stake in shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH) during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor acquired 20,689 shares of the medical equipment provider’s stock, valued at approximately $1,781,000.

A number of other hedge funds have also recently bought and sold shares of ZBH. BlackRock Inc. purchased a new position in shares of Zimmer Biomet during the 2nd quarter worth about $1,344,282,000. Norges Bank purchased a new stake in Zimmer Biomet in the fourth quarter valued at approximately $221,234,000. Franklin Resources Inc. increased its position in Zimmer Biomet by 43.2% during the fourth quarter. Franklin Resources Inc. now owns 6,685,987 shares of the medical equipment provider’s stock worth $601,204,000 after purchasing an additional 2,017,857 shares during the last quarter. Auto Owners Insurance Co raised its stake in Zimmer Biomet by 8,892.0% during the fourth quarter. Auto Owners Insurance Co now owns 2,009,712 shares of the medical equipment provider’s stock worth $180,713,000 after purchasing an additional 1,987,362 shares during the period. Finally, Equity Investment Corp purchased a new position in Zimmer Biomet during the second quarter worth approximately $144,748,000. Institutional investors and hedge funds own 88.89% of the company’s stock.

Wall Street Analyst Weigh In

ZBH has been the subject of several research reports. Truist Financial boosted their price objective on shares of Zimmer Biomet from $92.00 to $106.00 and gave the company a “hold” rating in a research note on Thursday, August 6th. Citizens Jmp cut their target price on Zimmer Biomet from $120.00 to $105.00 and set a “market outperform” rating on the stock in a research report on Wednesday, April 29th. Robert W. Baird set a $104.00 target price on Zimmer Biomet in a report on Thursday, August 6th. Zacks Research lowered Zimmer Biomet from a “hold” rating to a “strong sell” rating in a research note on Monday, July 27th. Finally, UBS Group restated a “buy” rating and issued a $120.00 price objective on shares of Zimmer Biomet in a report on Thursday, August 6th. One equities research analyst has rated the stock with a Strong Buy rating, six have given a Buy rating, thirteen have assigned a Hold rating and three have given a Sell rating to the stock. According to data from MarketBeat, the company has an average rating of “Hold” and an average target price of $104.42.

Zimmer Biomet Price Performance

Zimmer Biomet stock opened at $101.41 on Thursday. The firm has a fifty day moving average of $93.40 and a 200-day moving average of $91.31. Zimmer Biomet Holdings, Inc. has a 52-week low of $79.12 and a 52-week high of $107.85. The company has a quick ratio of 0.94, a current ratio of 1.69 and a debt-to-equity ratio of 0.50. The firm has a market capitalization of $19.34 billion, a P/E ratio of 24.67, a PEG ratio of 2.72 and a beta of 0.45.

Zimmer Biomet (NYSE:ZBH) last announced its quarterly earnings results on Wednesday, August 5th. The medical equipment provider reported $2.07 earnings per share for the quarter, topping analysts’ consensus estimates of $2.01 by $0.06. Zimmer Biomet had a net margin of 9.48% and a return on equity of 13.12%. The firm had revenue of $2.18 billion during the quarter, compared to analysts’ expectations of $2.13 billion. During the same period in the prior year, the company earned $2.07 EPS. The firm’s revenue was up 4.8% on a year-over-year basis. Zimmer Biomet has set its FY 2026 guidance at 8.470-8.590 EPS. As a group, analysts predict that Zimmer Biomet Holdings, Inc. will post 8.54 EPS for the current year.

Insider Activity at Zimmer Biomet

In other Zimmer Biomet news, insider Sang Yi sold 5,000 shares of the business’s stock in a transaction dated Friday, May 29th. The stock was sold at an average price of $82.64, for a total transaction of $413,200.00. Following the transaction, the insider owned 27,251 shares in the company, valued at $2,252,022.64. The trade was a 15.50% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. 1.28% of the stock is currently owned by corporate insiders.

Zimmer Biomet Profile

Zimmer Biomet (NYSE: ZBH) is a global medical device company focused on musculoskeletal healthcare. Headquartered in Warsaw, Indiana, the company designs, manufactures and markets a broad portfolio of products used to treat joint disorders, bone disorders and related conditions. Its customer base includes orthopaedic and dental surgeons, hospitals, ambulatory surgery centers and other healthcare providers that rely on implants, instruments and related services for reconstructive and restorative procedures.

The company’s product offerings span joint replacement systems for hips, knees and shoulders; trauma and extremities implants; spine and thoracic solutions; dental and craniomaxillofacial implants and prosthetics; and sports medicine devices.